Envoy Therapeutics Achieves Milestone in Diabetes and Obesity Alliance with Merck & Co., Inc.

Published: Dec 15, 2010

JUPITER, Fla.--(BUSINESS WIRE)--Envoy Therapeutics, Inc., a drug discovery company, today announced that it has reached a milestone in its strategic alliance with Merck (known outside the US and Canada as MSD). The milestone was linked to Envoy successfully applying its bacTRAP® technology in certain tissues that are important to diabetes and obesity. Achievement of the milestone has entitled Envoy to receive a cash payment from Merck.

Back to news